Lincoln Pharmaceuticals Hits New 52-Week Low at Rs. 491

Lincoln Pharmaceuticals has reached a new 52-week low, hitting Rs. 491 today, marking a significant decline in its stock performance. This drop comes after a brief two-day period of gains, with the stock underperforming its sector by 4.73%. The intraday low of Rs. 491 reflects a decrease of 6.69% from the previous trading session.
In terms of moving averages, Lincoln Pharmaceuticals is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent downward trend. Over the past year, the stock has experienced a decline of 19.42%, contrasting sharply with the Sensex, which has gained 8.76% during the same period.

Despite its microcap status, the company has shown limited growth, with net sales increasing at an annual rate of 9.87% and operating profit at 7.84% over the last five years. Additionally, the company's return on capital employed (ROCE) stands at a low 16.54%, and non-operating income constitutes a significant portion of profit before tax. These factors contribute to a challenging market position for Lincoln Pharmaceuticals as it navigates current financial conditions.